Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a tim…
Medical - Devices
US, Acton [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Insulet Corporation's gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2014 | -0.8300 | -0.330 | 247 | 193 | -44 | -210 | -29 | -97 | -29 | -53 | 119 | 82 |
| 2015 | -0.9300 | -1.071 | 288 | 315 | -51 | -60 | -12 | -37 | -12 | -50 | 127 | 136 |
| 2016 | -1.2900 | -0.374 | 263 | 363 | -73 | -33 | -32 | 1 | -48 | -11 | 138 | 202 |
| 2017 | -0.5000 | -0.440 | 366 | 458 | -28 | -23 | -9 | 10 | -10 | -5 | 166 | 198 |
| 2018 | -0.4600 | -0.035 | 463 | 561 | -26 | -2 | -7 | 44 | -7 | 17 | 210 | 240 |
| 2019 | 0.0559 | 0.223 | 563 | 728 | 3 | 29 | 27 | 153 | 27 | 91 | 254 | 622 |
| 2020 | 0.1900 | 0.325 | 738 | 891 | 11 | 23 | 50 | 71 | 50 | 27 | 300 | 381 |
| 2021 | 0.1100 | 0.129 | 904 | 1,091 | 6 | 4 | 54 | 141 | 51 | 130 | 384 | 546 |
| 2022 | 0.2500 | 0.416 | 1,098 | 1,268 | 16 | -70 | 124 | 114 | 126 | 12 | 466 | 1,028 |
| 2023 | 0.0663 | 1.990 | 1,305 | 1,648 | 4 | 395 | 36 | 126 | 37 | 13 | 587 | 1,131 |
| 2024 | 2.9600 | 3.671 | 1,697 | 2,016 | 206 | 270 | 220 | 160 | 220 | 63 | 734 | 862 |
| 2025 | - | 3.867 | - | 2,392 | - | 287 | - | 190 | - | 74 | - | 1,023 |
| 2026 | - | 4.876 | - | 2,817 | - | 2.F12X/td> | - | 2.F121/td> | - | 2.F121 | - | 2.F121 |
| 2027 | - | 6.333 | - | 3,340 | - | 1.F13X/td> | - | 1.F131/td> | - | 1.F131 | - | 1.F131 |
| 2028 | - | 7.265 | - | 3,623 | - | 0.F14X/td> | - | 0.F141/td> | - | 0.F141 | - | 0.F141 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
Overweight
Prev. Grade
Overweight
Nov. 6, 2024
Overweight
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
+5.82% + $15.29 · MISS
Nov. 6, 2024Price Then
$241.32
Price Target
$247.64
Price Now
$262.93